logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Phase 3b/4 Study Of Taltz - Quick Facts

Eli Lilly and Company (LLY) said Taltz demonstrated effectiveness in improving the signs and symptoms of active psoriatic arthritis in a Phase 3b/4 SPIRIT-Head-to-Head study. The trial demonstrated that Taltz was more effective than Humira in simultaneously achieving both joint and skin responses after 24 weeks of treatment. Topline results from the study were announced last year.

A total of 566 patients were enrolled in the study. Taltz also met the key secondary endpoints. The safety data were consistent with previously reported results.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT